Administering Esomeprazole as a Continuous Subcutaneous Infusion in the Palliative Demographic: A Retrospective Review.

Electronic records were examined for dose, duration, infusion characteristics, site reactions, indications, and symptom outcomes.

Symptomatic benefit was observed in over 70% of cases for symptoms relating to dyspepsia, malignant bowel obstruction, and gastrointestinal bleeding.

Esomeprazole as a continuous subcutaneous infusion appears safe, feasible, and clinically beneficial.